此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

FreeStyle Libre Glucose Monitoring System in Pediatric Populations

2019年1月24日 更新者:Abbott Diabetes Care

FreeStyle Libre Flash Glucose Monitoring System in Pediatric Populations

This study is a non-randomized, single-arm, multi-center study that is designed to evaluate the safety and effectiveness of the FreeStyle Libre Flash Glucose Monitoring Systems in pediatric populations.

研究概览

详细说明

Up to 85 subjects will be enrolled at up to four (4) clinical research sites in the United States. Subjects will wear two Sensors. Each Sensor will have a paired Reader that will be given to the subject. All Readers will be masked during the study (i.e. subjects will not be able to view glucose results obtained from the Sensor on the Reader screen). Subjects will be asked to perform at least 4 capillary Blood Glucose (BG) tests per day using the primary Reader. Interstitial glucose readings from each Sensor will be obtained with the corresponding Readers immediately following each BG test. Subjects will be instructed to report any problems with the device. Subjects will make four (4) to five (5) scheduled visits to the clinical study site, including the Enrollment/Screening Visit (Visit 1). Based on the subjects weight, subjects will have up to two (2) in-clinic visits during which intravenous blood draws and YSI reference testing will occur.

研究类型

观察性的

注册 (实际的)

63

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • California
      • Santa Barbara、California、美国、93105
        • Sansum Diabetes Research Institute
      • Walnut Creek、California、美国、94598
        • Diablo Clinical Research
    • Idaho
      • Idaho Falls、Idaho、美国、83404
        • Rocky Mountain Diabetes & Osteoporosis Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

6年 至 17年 (孩子)

接受健康志愿者

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Subjects aged 6-17 years, with type 1 or type 2 diabetes who currently perform capillary blood glucose (BG) testing at least four (4) times a day.

描述

  • Inclusion Criteria:

    • Subject must be at least 6 years of age.
    • Subject must weigh at least 26 kg (57.2 lbs.).
    • Subject must have a diagnosis of type 1 or type 2 diabetes mellitus
    • Subject must require insulin therapy through an insulin pump and/or multiple daily insulin injections (at least 3 injections daily).
    • Subject must be currently performing at least four (4) capillary blood glucose tests per day.
    • Subject is willing to perform a minimum of 4 finger sticks per day during the study.
    • Subject is willing to allow medical personnel to insert at IV catheter in the arm to allow for venous blood samples to be obtained per the study protocol.
    • Subject and/or guardian must be able to read and understand English.
    • In the investigator's opinion, the subject must be able to follow the instructions provided to him/her by the study site and perform all study tasks as specified by the protocol.
    • Subject must be available to participate in all study visits.
    • Subject must be willing and able to provide written signed and dated informed assent when appropriate.
    • Subject's parent, guardian or legally authorized representative must be willing and able to provide written informed consent.
  • Exclusion Criteria:

    • Subject is 18 years of age or older.
    • Subject weighs less than 26 kg (57.2 lbs.).
    • Subject has known allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin.
    • Subject is known to be pregnant or becomes pregnant during the study (applicable to female subjects only).
    • Subject has extensive skin changes/diseases at the proposed application sites that could interfere with device placement or the accuracy of interstitial glucose measurements. Such conditions include, but are not limited to extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, dermatitis herpetiformis, skin lesions, redness, infection or edema.
    • Subject is currently participating in another clinical trial.
    • Subject has had significant blood loss within 112 days (3.7 months) prior to the beginning of the study activities subjects.
    • Subject is anemic, defined as having hemoglobin levels below 11.5 g/dL for subjects aged 6-11 years old, less than 12.0 g/dL for subjects aged 12-15 years old, less than 12.0 g/dL for females aged 15-17 and less than 13.0 g/dL for males aged 15-171, or as determined by investigator.
    • Subject has X-ray, MRI or CT appointment scheduled during the period of study participation, and the appointment cannot be rescheduled for a time before study participation starts or after study participation ends.
    • Subject is unsuitable for participation due to any other cause as determined by the Investigator.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
FreeStyle Libre Flash Glucose Monitoring System Performance
大体时间:up to 14 days
System performance will be characterized with respect to YSI reference venous plasma sample measurements. Point accuracy of the system will be evaluated as the proportion of System readings that are within ±20% of the YSI reference value for YSI glucose levels ≥ 80 mg/dl and within ±20 mg/dl for YSI glucose levels <80 mg/dl.
up to 14 days
FreeStyle Libre Flash Glucose Monitoring System Related adverse device effects
大体时间:up to 45 days
System will be characterized by Adverse Device Effects and Serious Adverse Device Effects experienced by study participants.
up to 45 days

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Shridhara Alva, PhD、Abbot Diabetes care inc.

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2018年4月5日

初级完成 (实际的)

2018年7月3日

研究完成 (实际的)

2018年7月3日

研究注册日期

首次提交

2018年4月4日

首先提交符合 QC 标准的

2018年4月17日

首次发布 (实际的)

2018年4月18日

研究记录更新

最后更新发布 (实际的)

2019年1月28日

上次提交的符合 QC 标准的更新

2019年1月24日

最后验证

2018年4月1日

更多信息

与本研究相关的术语

其他研究编号

  • ADC-US-VAL-18172

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

药物和器械信息、研究文件

研究美国 FDA 监管的药品

研究美国 FDA 监管的设备产品

是的

在美国制造并从美国出口的产品

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

糖尿病的临床试验

FreeStyle Libre Flash 血糖监测系统的临床试验

订阅